Entia Biosciences Inc. Stock Analysis ERGO
Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
Read More Entia Biosciences Inc (ERGO) Chart
Key Statistics of Entia Biosciences Inc (ERGO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
6500.00P/E Ratio (TTM)
-52 Week Range
Market Cap
20.20KAvg. Volume
3300.00Dividend Yield
-Financial Metrics & Statements of Entia Biosciences Inc (ERGO)
FAQ's for Entia Biosciences Inc (ERGO)
- According to Musaffa’s Shariah screening methodology, Entia Biosciences Inc (ERGO) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.